30 closest matches · ranked by relevance
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Ureteral Obstruction
Primary: Mean Stent Dwell Time — 17; 3.97 months
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Recurrent Bladder Cancer · Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria — 0 participants
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
Urothelial Cancer
Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Advanced Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Prostate Carcinoma
Primary: Overall Survival (OS) — 14.5; 14.3 months — p=0.1707
Bladder Cancer
Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Bladder Cancer · Metastatic Transitional Cell Carcinoma
Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants
Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Proximal Urethral Cancer
Primary: Objective Response Rate — 56.4 percentage of participants
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Non-Transitional Cell Carcinoma of the Urothelial Tract · Small Cell of the Bladder · Adenocarcinoma of the Bladder
Primary: Overall Response Rate — 2; 11; 2 Participants
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Urologic Neoplasms
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) — 44; 51.7 Percentage of Participants
High Grade Upper Tract Urothelial Carcinoma
Primary: Complete Pathologic Response Rate — 0.103; 0.167 proportion of participants
Carcinoma, Transitional Cell · Transitional Cell Carcinoma of Renal Pelvis
Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants
Bladder Cancer
Primary: Complete Response Rate at the End of Induction — 46 percentage of participants
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Urothelial Carcinoma · Bladder Cancer · Urinary Bladder Neoplasms
Primary: Percentage of Participants Who Enrolled and Underwent a Biopsy Who Went on to Receive Treatment Within 21 Days — 63 percentage of participants
Transitional Cell Carcinoma of Bladder · Superficial Bladder Cancer
Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)
Carcinoma of Urinary Tract · Urethral Carcinoma · Carcinoma of Ureter
Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months